Form 4: Monopar Director Klausner Receives Stock Options

Monopar Therapeutics director Arthur J. Klausner was granted 2,924 stock options with an exercise price of $75.94, vesting quarterly through 2026.

Summary

• Arthur J. Klausner, a Director of Monopar Therapeutics (MNPR), was granted 2,924 stock options.
• The options have an exercise price of $75.94 per share.
• The transaction date for this grant was December 2, 2025.
• The options will vest 25% quarterly on March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026.
• The expiration date for these options is December 2, 2035.
• Following this transaction, Mr. Klausner beneficially owns 2,924 derivative securities.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The grant of options is a routine compensation event that aligns director interests with shareholders, but does not provide new operational or financial performance data.

Positives

• The grant of stock options to Director Arthur J. Klausner aligns his interests with those of shareholders, incentivizing long-term company performance.
• The options have a 10-year expiration date, providing a significant window for potential value realization.

Negatives

• No specific negative aspects are detailed in this routine insider transaction report.

Risks

• The value of the stock options is dependent on the future market price of Monopar Therapeutics common stock exceeding the exercise price of $75.94.
• There is a risk that the options may expire worthless if the stock price does not rise above the exercise price.

Future Outlook

The vesting schedule indicates that the director's full ownership of these options will be realized over the course of 2026, contingent on continued service. The long expiration date provides a future incentive for stock price appreciation.

Industry Context

Granting stock options to directors is a common practice in the biotechnology and pharmaceutical industry, including companies like Monopar Therapeutics, to attract and retain talent and align leadership interests with long-term shareholder value. This is a standard form of equity compensation.

Comparison to Industry Standards

• The grant of stock options to a director is a standard compensation practice, comparable to similar grants observed at other small-cap biotechnology companies.
• The vesting schedule (quarterly over one year) and 10-year expiration period are typical for director equity awards in the industry, aiming to provide long-term incentives.
• Specific comparable companies or projects are not detailed in this filing, but the structure aligns with general industry benchmarks for non-executive director compensation.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's interests with shareholders, potentially leading to better long-term performance. However, future exercise of these options could result in minor dilution.
• Employees: No direct impact on employees is mentioned in this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is mentioned.

Next Steps

• The options will vest quarterly, with the first vesting on March 31, 2026, and the final vesting on December 31, 2026.
• The director may choose to exercise these options at any time after vesting and before the expiration date of December 2, 2035, assuming the stock price is favorable.

Key Dates

Keywords

Monopar Therapeutics, MNPR, Form 4, stock options, insider transaction, director compensation, equity grant, vesting schedule